Lupin Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 11, 2026

Key Highlights

The Latest Trading Price of Lupin Ltd is ₹ 2270 as of 11 Jun 11:33 . The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Lupin Ltd changed from ₹ 46318 crore on March 2021 to ₹ 92522 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Lupin Ltd for the Mar '26 is ₹ 7615 crore as compare to the Dec '25 revenue of ₹ 7282 crore. This represent the growth of 4.57% The revenue of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 149.97 crore as compare to the Dec '25 revenue of ₹ 120.64 crore. This represent the growth of 24.31% The ebitda of Lupin Ltd for the Mar '26 is ₹ 2494 crore as compare to the Dec '25 ebitda of ₹ 1949 crore. This represent the growth of 27.95% The ebitda of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 36.56 crore as compare to the Dec '25 ebitda of ₹ 26.71 crore. This represent the growth of 36.88% The net profit of Lupin Ltd changed from ₹ 805.54 crore to ₹ 1468 crore over 8 quarters. This represents a CAGR of 35.03% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 25.17 crore over 8 quarters. This represents a CAGR of 81.63% The Dividend Payout of Lupin Ltd changed from 23.43 % on March 2021 to 13.79 % on March 2025 . This represents a CAGR of -10.06% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Lupin Ltd

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Lupin Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Lupin Ltd or Syncom Formulations (India) Ltd?

Market cap of Lupin Ltd is 102,817 Cr while Market cap of Syncom Formulations (India) Ltd is 1,327 Cr

What are the key factors driving the stock performance of Lupin Ltd and Syncom Formulations (India) Ltd?

The stock performance of Lupin Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Syncom Formulations (India) Ltd?

As of June 11, 2026, the Lupin Ltd stock price is INR ₹2248.7. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.12.

How do dividend payouts of Lupin Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Lupin Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.